Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease

Carl E. Frasch; Ray Borrow; John Donnelly

doi:10.1016/j.vaccine.2009.04.065

Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease

Carl E. Frasch^*, Ray Borrow, John Donnelly

^*Corresponding author for this work

Manchester Meningococcal Reference Unit General

Research output: Contribution to journal › Article › peer-review

177 Citations (Scopus)

Abstract

It has been demonstrated that antibodies induced by meningococcal polysaccharide, polysaccharide-protein conjugates and outer membrane protein vaccines protect against meningococcal disease. This review will show that the induced antibody protects via complement mediated bactericidal killing and that induction of serum bactericidal antibody (SBA) is a good surrogate for efficacy. The critical role of SBA is shown by: (1) Highest incidence of meningococcal disease occurs in infants between 6 and 18 months of age, who have the lowest levels of SBA. (2) Studies published in 1969 in US Army recruits showed a direct correlation between susceptibility to meningococcal disease and absence of SBA. (3) Meningococcal polysaccharide, polysaccharide-protein conjugates, and outer membrane vesicle vaccines all induce SBA shown to be effective in direct proportion to the percent of vaccinees with SBA activity.

Original language	English
Pages (from-to)	B112-B116
Journal	Vaccine
Volume	27
Issue number	SUPPL. 2
DOIs	https://doi.org/10.1016/j.vaccine.2009.04.065
Publication status	Published - 24 Jun 2009

Bibliographical note

Funding Information:
CEF: Consultant (Novartis Vaccines and Diagnostics; GlaxoSmithKline-Biologicals). JD: Employee Novartis Vaccines and Diagnostics. RB: Assistance to attend scientific meetings from Wyeth, Novartis, Sanofi Pasteur, Baxter Bioscience; ad hoc consultant for Wyeth, GlaxoSmithKline, Novartis, Sanofi Pasteur, Baxter Bioscience; industry honoraria for consulting, lecturing and writing are paid directly into Central Manchester and Manchester Children's University Hospitals NHS Trust endowment fund; contract research on behalf of the Health Protection Agency (funded by Wyeth, Novartis Vaccines, Baxter Bioscience, GlaxoSmithKline, Sanofi Pasteur, Alexion Pharmaceuticals Inc, Emergent Europe, Merck).

Keywords

Bactericidal
Biomarker
Immunity

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.vaccine.2009.04.065

Cite this

@article{d288dbad50b84fe9a1c85f1580165c33,

title = "Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease",

abstract = "It has been demonstrated that antibodies induced by meningococcal polysaccharide, polysaccharide-protein conjugates and outer membrane protein vaccines protect against meningococcal disease. This review will show that the induced antibody protects via complement mediated bactericidal killing and that induction of serum bactericidal antibody (SBA) is a good surrogate for efficacy. The critical role of SBA is shown by: (1) Highest incidence of meningococcal disease occurs in infants between 6 and 18 months of age, who have the lowest levels of SBA. (2) Studies published in 1969 in US Army recruits showed a direct correlation between susceptibility to meningococcal disease and absence of SBA. (3) Meningococcal polysaccharide, polysaccharide-protein conjugates, and outer membrane vesicle vaccines all induce SBA shown to be effective in direct proportion to the percent of vaccinees with SBA activity.",

keywords = "Bactericidal, Biomarker, Immunity",

author = "Frasch, {Carl E.} and Ray Borrow and John Donnelly",

note = "Funding Information: CEF: Consultant (Novartis Vaccines and Diagnostics; GlaxoSmithKline-Biologicals). JD: Employee Novartis Vaccines and Diagnostics. RB: Assistance to attend scientific meetings from Wyeth, Novartis, Sanofi Pasteur, Baxter Bioscience; ad hoc consultant for Wyeth, GlaxoSmithKline, Novartis, Sanofi Pasteur, Baxter Bioscience; industry honoraria for consulting, lecturing and writing are paid directly into Central Manchester and Manchester Children's University Hospitals NHS Trust endowment fund; contract research on behalf of the Health Protection Agency (funded by Wyeth, Novartis Vaccines, Baxter Bioscience, GlaxoSmithKline, Sanofi Pasteur, Alexion Pharmaceuticals Inc, Emergent Europe, Merck).",

year = "2009",

month = jun,

day = "24",

doi = "10.1016/j.vaccine.2009.04.065",

language = "English",

volume = "27",

pages = "B112--B116",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier",

number = "SUPPL. 2",

}

TY - JOUR

T1 - Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease

AU - Frasch, Carl E.

AU - Borrow, Ray

AU - Donnelly, John

N1 - Funding Information: CEF: Consultant (Novartis Vaccines and Diagnostics; GlaxoSmithKline-Biologicals). JD: Employee Novartis Vaccines and Diagnostics. RB: Assistance to attend scientific meetings from Wyeth, Novartis, Sanofi Pasteur, Baxter Bioscience; ad hoc consultant for Wyeth, GlaxoSmithKline, Novartis, Sanofi Pasteur, Baxter Bioscience; industry honoraria for consulting, lecturing and writing are paid directly into Central Manchester and Manchester Children's University Hospitals NHS Trust endowment fund; contract research on behalf of the Health Protection Agency (funded by Wyeth, Novartis Vaccines, Baxter Bioscience, GlaxoSmithKline, Sanofi Pasteur, Alexion Pharmaceuticals Inc, Emergent Europe, Merck).

PY - 2009/6/24

Y1 - 2009/6/24

N2 - It has been demonstrated that antibodies induced by meningococcal polysaccharide, polysaccharide-protein conjugates and outer membrane protein vaccines protect against meningococcal disease. This review will show that the induced antibody protects via complement mediated bactericidal killing and that induction of serum bactericidal antibody (SBA) is a good surrogate for efficacy. The critical role of SBA is shown by: (1) Highest incidence of meningococcal disease occurs in infants between 6 and 18 months of age, who have the lowest levels of SBA. (2) Studies published in 1969 in US Army recruits showed a direct correlation between susceptibility to meningococcal disease and absence of SBA. (3) Meningococcal polysaccharide, polysaccharide-protein conjugates, and outer membrane vesicle vaccines all induce SBA shown to be effective in direct proportion to the percent of vaccinees with SBA activity.

AB - It has been demonstrated that antibodies induced by meningococcal polysaccharide, polysaccharide-protein conjugates and outer membrane protein vaccines protect against meningococcal disease. This review will show that the induced antibody protects via complement mediated bactericidal killing and that induction of serum bactericidal antibody (SBA) is a good surrogate for efficacy. The critical role of SBA is shown by: (1) Highest incidence of meningococcal disease occurs in infants between 6 and 18 months of age, who have the lowest levels of SBA. (2) Studies published in 1969 in US Army recruits showed a direct correlation between susceptibility to meningococcal disease and absence of SBA. (3) Meningococcal polysaccharide, polysaccharide-protein conjugates, and outer membrane vesicle vaccines all induce SBA shown to be effective in direct proportion to the percent of vaccinees with SBA activity.

KW - Bactericidal

KW - Biomarker

KW - Immunity

UR - http://www.scopus.com/inward/record.url?scp=67349179167&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2009.04.065

DO - 10.1016/j.vaccine.2009.04.065

M3 - Article

C2 - 19464093

AN - SCOPUS:67349179167

SN - 0264-410X

VL - 27

SP - B112-B116

JO - Vaccine

JF - Vaccine

IS - SUPPL. 2

ER -

Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this